The hematopoietic saga of clonality in sickle cell disease
Open Access
- 1 March 2022
- journal article
- editorial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (5)
Abstract
Sickle cell disease (SCD) is associated with an increased risk of vascular-occlusive events and of leukemia. Clonal hematopoiesis (CH) may increase both risks. In turn, physiologic abnormalities in SCD may modify the incidence and/or distribution of genetic alterations in CH. In a recent issue of the JCI, Liggett et al. found no difference in CH rate between individuals with versus without SCD. Here we contextualize this report and discuss the complex interplay between CH and SCD with particular attention to consequences for emerging gene therapies. We further consider the limitations in our current understanding of these topics that must be addressed in order to optimize therapeutic strategies for SCD.Keywords
This publication has 20 references indexed in Scilit:
- Prediction of acute myeloid leukaemia risk in healthy individualsNature, 2018
- Increased risk of leukemia among sickle cell disease patients in CaliforniaBlood, 2017
- Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult LifeThe American Journal of Human Genetics, 2017
- Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell diseaseLeukemia & Lymphoma, 2017
- Sickle Cell DiseaseNew England Journal of Medicine, 2017
- Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage studyJournal of the Royal Society of Medicine, 2016
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014
- Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is nowBlood, 2011
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)Blood, 2010
- Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell AnemiaJAMA, 2003